The development of new preventive measures and therapeutic methods in the management of hand-foot syndrome by multi-kinase inhibitors sorafenib.

The development of new preventive measures and therapeutic methods in the management of hand-foot syndrome by multi-kinase inhibitors sorafenib. - The development of new preventive measures and therapeutic methods in the management of hand-foot syndrome by multi-kinase inhibitors sorafenib.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032026

Enrollment

Registered

2018-03-30

Start date

2017-11-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepastocellular cancer(HCC)

Interventions

12 weeks /Application of aluminium chloride ointment once a day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Cancer patients who are scheduled to be on Sorafeniv. 2)Patients who are scheduled to be on the drugs with standard dosage 3) PS0-1 4) Written informed consent for this study can be obtained from the patients.

Exclusion criteria

Exclusion criteria: 1) Patients with fissure or erosion in the palmoplantar area 2) Patients with a history of sympathectomy

Design outcomes

Primary

Measure	Time frame
Incidence of Grade 3 HFS	—

Countries

Japan

Contacts

Public ContactAya Nishizawa

National Defense Medical College Dermatology

ayanishiza@yahoo.co.jp04-2995-1665

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026